WallStreetZenWallStreetZen

NASDAQ: ACAD
Acadia Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Acadia Pharmaceuticals earnings were $261.2M for the trailing 12 months ending Sep 30, 2025, with 101.3% growth year over year. The latest ACAD earnings report on Sep 30, 2025 announced Q3 2025 earnings of $71.8M, up 169.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ACAD reported annual earnings of $226.5M, with -469.5% growth.

ACAD past earnings growth

How has ACAD's earnings growth performed historically?

Company
101.28%
Industry
62.5%
Market
55.53%
ACAD's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ACAD's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ACAD's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ACAD earnings history

Current Revenue
$1.0B
Current Earnings
$261.2M
Current Profit Margin
24.9%

ACAD Return on Equity

Current Company
32.3%
Current Industry
-21.3%
Current Market
36.1%
ACAD's Return on Equity (32.3%)... subscribe to Premium to read more.
High Return on Equity Performance

ACAD undefined

Current Company
21.4%
Current Industry
-8.8%
ACAD is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ACAD announces earnings.

ACAD undefined

Current Company
28.09%
Current Industry
-3.4%
ACAD has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ACAD vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ACAD$287.72M$261.17M+101.28%$1.57
IMVT-$461.93M-$464.69MN/A-$2.83
ACLX-$242.23M-$217.90MN/A-$3.93
VKTX-$236.95M-$237.39MN/A-$2.12
CRNX-$416.29M-$423.10MN/A-$4.52
View Top Biotech Stocks

Acadia Pharmaceuticals Earnings Reports & History FAQ

What were Acadia Pharmaceuticals's earnings last quarter?

On ACAD's earnings call on Invalid Date, Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q3 2025 earnings per share (EPS) of $0.43, up 115% year over year. Total ACAD earnings for the quarter were $71.78 million. In the same quarter last year, Acadia Pharmaceuticals's earnings per share (EPS) was $0.20.

If you're new to stock investing, here's how to buy Acadia Pharmaceuticals stock.

Is Acadia Pharmaceuticals profitable or losing money?

As of the last Acadia Pharmaceuticals earnings report, Acadia Pharmaceuticals is currently profitable. Acadia Pharmaceuticals's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $261.17 million, a 103.24% increase year over year.

What was ACAD's earnings growth in the past year?

As of Acadia Pharmaceuticals's earnings date in Invalid Date, Acadia Pharmaceuticals's earnings has grown 101.28% year over year. This is 38.78 percentage points higher than the US Biotechnology industry earnings growth rate of 62.5%. ACAD earnings in the past year totalled $261.17 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.